Interpace's ThyraMir Receives Coverage From UnitedHealthcare

Apr 18, 2017

|

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyraMir test for diagnosing thyroid cancer has received coverage from UnitedHealthcare.

With this coverage decision, ThyraMir is now covered for around 250 million patients nationwide, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Interpace's ThyraMir Receives Coverage From UnitedHealthcare

To read the full story....

Breaking News

Biden Unveils Economic Plan to Provide $50B for COVID-19 Testing Expansion

Report Details COVID-19 Testing Within Federal Government

In Brief This Week: Thermo Fisher, Yourgene Health, Deep Lens, and More

DARPA Awards $36.7M to Six Organizations for Gene Editing-Based Dx, Biosurveillance Tech

FDA Grants Emergency Use Authorization for SML Genetree Molecular Coronavirus Test

Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Jonathan Rothberg-Led Startup Looks to Bring Disposable POC SARS-CoV-2 Test to Market

JP Morgan Healthcare Conference 2021, Day One: Roche, Guardant, Hologic, Thermo Fisher, and More

Report Details COVID-19 Testing Within Federal Government

JP Morgan Healthcare Conference, Day 3: Exact Sciences, Luminex, Danaher, Siemens Healthineers, and More

At JP Morgan Conference, Quidel CEO Discusses Plan to Enter OTC Infectious Disease Test Market

Sponsorships